Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 7/20 | 0.32 |
| ▸ | TYR | P14679 | 2/20 | 0.32 |
| ▸ | DHFR | P00374 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7530621 | 0.88 | KCNH2 (0.38) | TLR8TYRMEN1TP53CYP3A4 | |
| SCHEMBL7056015 | 0.88 | KCNH2 (0.38) | TLR8TYRMEN1TP53CYP3A4 | |
| SCHEMBL7580690 | 0.88 | KCNH2 (0.38) | TLR8TYRMEN1TP53CYP3A4 | |
| SCHEMBL7717379 | 0.86 | KCNH2 (0.37) | TLR8TYRMEN1TP53CYP3A4 | |
| SCHEMBL7572175 | 0.86 | KCNH2 (0.35) | TLR8TYRMEN1TP53CYP3A4 | |
| SCHEMBL8923586 | 0.79 | S1PR1 (0.44) | MEN1ALOX15TSHRKMT2ATDP1 | |
| SCHEMBL7533536 | 0.74 | LIPG (0.34) | TLR8CYP3A4MAPTTSHR | |
| SCHEMBL8958465 | 0.72 | HSD17B10 (0.39) | TLR8MEN1CYP3A4MAPTTSHR | |
| SCHEMBL10595842 | 0.72 | CYSLTR2 (0.44) | TLR8MEN1KMT2A | |
| SCHEMBL7595832 | 0.72 | MAPK14 (0.40) | CYP3A4MAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7563818-B2 | Photosensitizer functionalised nanoparticles | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-07-21 | — | — | US | disclosed |
| EP-1455828-B1 | PHOTOSENSITIZER FUNCTIONALISED NANOPARTICLES | CANCER REC TECH LTD (GB) | 2006-08-02 | — | — | EP | disclosed |
| US-20050058713-A1 | Photosensitizer functionalised nanoparticles | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2005-03-17 | — | — | US | disclosed |
| EP-1455828-A2 | PHOTOSENSITIZER FUNCTIONALISED NANOPARTICLES | University of East Anglia (GB) | 2004-09-15 | — | — | EP | disclosed |
| WO-2003037297-A2 | PHOTOSENSITIZER FUNCTIONALISED NANOPARTICLES | UNIVERSITY OF EAST ANGLIA (GB) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050058713-A1 | Photosensitizer functionalised nanoparticles | PPOX, SAMSN1, ICMT | SPHK2 3109/4885TLR8 4086/4885TYR 199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.